Vaccine最新文献

{"title":"The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination","authors":"Yu Jung Choi ,&nbsp;Jaehun Jung ,&nbsp;Minsun Kang ,&nbsp;Min Joo Choi ,&nbsp;Won Suk Choi ,&nbsp;Yu Bin Seo ,&nbsp;Hak-Jun Hyun ,&nbsp;Yoonsun Yoon ,&nbsp;Young June Choe ,&nbsp;Geum Joon Cho ,&nbsp;Young-Eun Kim ,&nbsp;Dong Wook Kim ,&nbsp;Hye Seong ,&nbsp;Eliel Nham ,&nbsp;Jin Gu Yoon ,&nbsp;Ji Yun Noh ,&nbsp;Joon Young Song ,&nbsp;Woo Joo Kim ,&nbsp;Hee Jin Cheong","doi":"10.1016/j.vaccine.2024.126506","DOIUrl":"10.1016/j.vaccine.2024.126506","url":null,"abstract":"<div><h3>Introduction</h3><div>Coronavirus 2019 (COVID-19) vaccination rates in pregnant women remain low owing to safety concerns. When evaluating vaccine safety, comparisons with unvaccinated individuals may lead to healthy vaccinee bias. This study aimed to investigate the association between mRNA-based COVID-19 vaccination and pregnancy-related adverse outcomes compared with influenza vaccination.</div></div><div><h3>Methods</h3><div>A propensity score-matched cohort study was conducted using the National Health Insurance Service insurance claims database, combined with COVID-19 and influenza vaccination registration data from the Korea Disease Control and Prevention Agency. Based on the age, comorbidities, insurance type, region, hospital type, gestational age at vaccination, and primiparity, the COVID-19 vaccination-only group and influenza vaccination-only group were matched in a 1:3 ratio, while both (COVID-19 and influenza) vaccination group and influenza vaccination-only group were also matched in a 1:3 ratio. Logistic regression analysis was used to calculate odds ratios (ORs) with 95 % confidence intervals (CIs) between the two groups.</div></div><div><h3>Results</h3><div>From October 18, 2021, to March 3, 2022, 71,902 pregnant women were identified, and the vaccination records of 67,522 individuals were verified. Among them, 610 received the COVID-19 vaccination only, 49,952 received the influenza vaccination only, and 2405 received both vaccines. In the COVID-19 vaccination-only group, the risk of large for gestational age was higher than in the influenza vaccination-only group (OR = 2.285, 95 % CI = 1.155–4.522, <em>P</em> = 0.018). In the group that received both vaccinations, the risk of premature birth was higher (OR = 1.365, 95 % CI = 1.124–1.656, <em>P</em> = 0.002) than that in the influenza vaccination-only group but lower than the domestic baseline incidence rates. No significant differences were observed in other maternal and neonatal outcomes.</div></div><div><h3>Conclusion</h3><div>mRNA-based COVID-19 vaccination in pregnant women is safe without a remarkable increase in adverse maternal and neonatal outcomes. Given the high morbidity and mortality rates of COVID-19 in pregnant women, it is reasonable to recommend COVID-19 vaccination for pregnant women.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"44 ","pages":"Article 126506"},"PeriodicalIF":4.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease","authors":"Natalie E. Dean ,&nbsp;M. Elizabeth Halloran ,&nbsp;Veronika I. Zarnitsyna","doi":"10.1016/j.vaccine.2024.126516","DOIUrl":"10.1016/j.vaccine.2024.126516","url":null,"abstract":"<div><div>Vaccines can reduce an individual's risk of infection and their risk of progression to severe disease given infection. The latter effect is less commonly estimated but is relevant for vaccine impact modeling and cost-effectiveness calculations. Using a motivating example from the COVID-19 literature, we note how vaccine effectiveness against progression to severe disease can appear to increase from below 0 % to over 70 % within 8 months. With true biological strengthening of this magnitude being unlikely, we use a mathematical modeling framework to identify parameter combinations where this phenomenon can occur. Fundamental features are an immunocompetent population with high initial protection against infection, contrasted with a vulnerable subpopulation with poor vaccine response against infection and progression. As a result, the earliest infections are among those with the weakest protection against severe disease. This work highlights methodological challenges in isolating a vaccine's effect on progression to severe disease after infection, and it signals the need for refined analytical methods to adjust for differences between the vaccinated infected and the unvaccinated infected populations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126516"},"PeriodicalIF":4.5,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between family planning, healthcare access, and female education and vaccination among under-immunized children","authors":"Francisco Castillo-Zunino ,&nbsp;Kyra A. Hester ,&nbsp;Pinar Keskinocak ,&nbsp;Dima Nazzal ,&nbsp;Hannah K. Smalley ,&nbsp;Matthew C. Freeman","doi":"10.1016/j.vaccine.2024.126540","DOIUrl":"10.1016/j.vaccine.2024.126540","url":null,"abstract":"<div><h3>Background</h3><div>Increasing childhood vaccination, family planning, healthcare access, and women's empowerment are targets of the Sustainable Development Goals (SDG). Barriers to healthcare access impede vaccination; tackling goals holistically could create larger gains than siloed efforts. We studied Nepal, Senegal, and Zambia to test the association between childhood vaccinations and other SDG indicators to identify clustered deprivations. We quantified how under-immunized children with few – or no – vaccines and their mothers were vulnerable in SDG areas.</div></div><div><h3>Methods</h3><div>We analyzed Demographic and Health Surveys from Nepal, Senegal, and Zambia. Through ordinal logistic regressions, controlling for household/mother's characteristics, we identified strong predictors of the number of vaccine doses one-year-old children received. Through bootstrapping and optimal propensity scores matching, we compared children with no or few vaccine doses (0–2 doses in early 2000s, or 0–4 in late 2010s) to children who received eight doses (DTP1–3, MVC1, Pol1–3, and BCG vaccines).</div></div><div><h3>Findings</h3><div>Mothers of children who received eight doses were 14–30 % more likely than mothers of children with few or no doses to have accessed a health facility in the last year (95 % CIs were 16–44 % in Nepal 2001, −5 % to 33 % Nepal 2016, 3–26 % Senegal 2005, 1–31 % Senegal 2019, 9–38 % Zambia 2001–02, 7–36 % Zambia 2018), knew on average 0.7–1.5 more contraceptive methods (0.9–2.0 Nepal 2005, 0.1–1.5 Nepal 2016, 0.6–1.7 Senegal 2005, 0.2–1.7 Senegal 2019, 0.1–1.4 Zambia 2001–02, 0.5–1.4 Zambia 2018), and had 10–22 % higher literacy rates (12–32 % Nepal 2001, −7 % to 36 % Nepal 2016, 10–26 % Senegal 2005, −3 to 22 % Senegal 2019, −4 % to 28 % Zambia 2001–02, 5–36 % Zambia 2018).</div></div><div><h3>Interpretation</h3><div>Children with few or no vaccine doses and their mothers were behind in access to family planning, healthcare, and education compared to fully vaccinated children and their mothers. Such differences can further impede immunizations; integrated education and health services are needed to improve vaccination outcomes.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"44 ","pages":"Article 126540"},"PeriodicalIF":4.5,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142707276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China","authors":"Minjung Lee ,&nbsp;Chenyuan Qin ,&nbsp;Yubin Lee ,&nbsp;Jie Deng ,&nbsp;Myoungsoon You ,&nbsp;Jue Liu","doi":"10.1016/j.vaccine.2024.126515","DOIUrl":"10.1016/j.vaccine.2024.126515","url":null,"abstract":"<div><h3>Background</h3><div>It is crucial to emphasize the necessity of annual COVID-19 vaccination, particularly for vulnerable populations like older and chronically ill individuals.</div></div><div><h3>Objectives</h3><div>This study aimed to quantify the level of vaccination acceptance and its 5C psychological antecedents in the South Korean and Chinese populations and also to identify the predictors, considering contextual variations that influence vaccine acceptance in both countries.</div></div><div><h3>Methods</h3><div>A cross-sectional survey study was undertaken in South Korea and China between March 15 and March 30, 2023, coinciding with the emergence of the SARS-CoV-2 Omicron variant in both nations. The study comprised 1000 participants from South Korea and 3000 participants from China. A chi-square analysis, <em>t</em>-tests and multivariable logistic regression analysis were employed to evaluate the factors influencing the acceptance of COVID-19 vaccines.</div></div><div><h3>Results</h3><div>A higher degree of vaccine acceptance was observed among Chinese participants (48.5 %), in contrast to the 16.8 % among South Koreans. Analyzing the psychological antecedents for vaccination, the Chinese cohort showed high vaccine confidence, whereas South Koreans had increased constraint perceptions. Psychological antecedents, particularly Confidence, play a significant positive role in vaccine acceptance in both South Korea (OR 2.98, CI [2.26–4.01], <em>p</em> &lt; 0.001) and China (OR 2.93, CI [2.58–3.33], p &lt; 0.001), while Constraints in South Korea (OR 0.83, CI [0.69–0.99], <em>p</em> &lt; 0.05) and China (OR 0.86, CI [0.79–0.94], p &lt; 0.001) contribute negatively to vaccine acceptance. Notably, divergent trends in the impact of age and underlying health conditions on vaccine acceptance were observed.</div></div><div><h3>Conclusions</h3><div>This study reveals a substantial disparity in acceptance, psychological antecedents, and predictors of vaccine acceptance between China and South Korea. This importance of understanding contextual factors influencing public vaccine acceptance is emphasized. There is an urgent need for robust vaccination strategies that boost confidence and alleviate constraints to COVID-19 vaccination, which should be tailored to the unique contextual factors of each country.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126515"},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac®, Zoetis™): Evaluation of dose-dependent effectiveness and long-term immunity","authors":"Dan Gleser ,&nbsp;Michal Cohen ,&nbsp;Gabriel Kenigswald ,&nbsp;Maor Kedmi ,&nbsp;Benny Sharir ,&nbsp;Eyal Klement","doi":"10.1016/j.vaccine.2024.126531","DOIUrl":"10.1016/j.vaccine.2024.126531","url":null,"abstract":"<div><div>Bovine Ephemeral Fever (BEF) is an arthropod-borne virus (arbovirus) that presents a significant challenge to the cattle industry due to its economic impact<strong>,</strong> primarily through the loss of milk production in dairy cows. Vaccination is the predominant strategy for managing the disease. We recently showed a vaccine effectiveness (VE) of 60 % of a vaccine based on the Australian 919 BEFV isolate, with a natural challenge occurring shortly after the administration of the second dose of the vaccine. Still, there is a lack of data regarding the duration of protective immunity after vaccination and its potential enhancement after the administration of three and four vaccine doses. To answer these questions we conducted a retrospective cohort study of 850 cows (7 herds), analyzing the influence of different vaccination regimens on VE and a serosurvey of 71 cows to test the longevity of BEFV-specific serum-neutralizing antibodies (SNAb). We adopted a quantitative methodology for BEF diagnosis with the use of commercially validated precision dairy monitoring technologies for milk reduction identification. Survival analysis was used to analyze the vaccine dose effectiveness. A Cox regression mixed-effect model (COXME) was fitted to the data. The analysis demonstrated the following VE compared to zero vaccine doses: 82 % (<em>p</em>-value&lt;0.001) for four doses, 66 % (p-value&lt;0.026) for three doses and 39 % (p-value = 0.3) for two doses. Corroborating with the VE results, the four-dose regimen exhibited the highest geometric mean titer (GMT) value (4.45, CI_95% = 3.99, 4.91), followed by the three-dose regimen (3.53, CI_95% = 3.08,3.98), and the two-dose regimen (2.17, CI_95% = 1.77,2.57). In light of these findings, we recommend vaccinating calves as early as four to six months old with two doses spaced one month apart, followed by a third and even fourth dose administered between six to 12 months later, ideally close to the onset of the high-risk season.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126531"},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage","authors":"Yuping Tsai ,&nbsp;Jessica Leung ,&nbsp;Tara C. Anderson ,&nbsp;Fangjun Zhou ,&nbsp;James A. Singleton","doi":"10.1016/j.vaccine.2024.126537","DOIUrl":"10.1016/j.vaccine.2024.126537","url":null,"abstract":"<div><h3>Introduction</h3><div>The Inflation Reduction Act (IRA) eliminated cost sharing for Medicare Part D-covered vaccines but did not address the cost burden faced by Medicare beneficiaries who did not have prescription drug coverage. This study aimed to determine the characteristics of beneficiaries without prescription drug coverage and to assess the association between the receipt of a herpes zoster vaccine and prescription drug coverage status.</div></div><div><h3>Methods</h3><div>We used the 2019–2023 National Health Interview Survey and included Medicare beneficiaries aged 65 years and older who enrolled in both Parts A and B or a Medicare Advantage plan. Descriptive statistics were used to examine beneficiaries' characteristics. Logistic regressions were used to examine the associations between the receipt of a herpes zoster vaccine and Medicare prescription drug coverage.</div></div><div><h3>Results</h3><div>The study included 33,578 beneficiaries and 93.5 % of beneficiaries had prescription drug coverage. The prevalence of lacking prescription drug coverage was higher among beneficiaries who did not have a college degree, had family income below the poverty level, had no flu shot and well visit within the past year, and had no usual place for care. The probability of receiving a herpes zoster vaccine was higher among beneficiaries with prescription drug coverage than those without prescription coverage (45.2 % versus 25.3 %).</div></div><div><h3>Conclusions</h3><div>Herpes zoster vaccination disparities between beneficiaries with and without prescription drug coverage existed before the IRA. Because the IRA only addresses the cost barrier facing by beneficiaries with prescription drug coverage, vaccination disparities was greater after the IRA implementation.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126537"},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines","authors":"Nicholas S. Reed ,&nbsp;Carmen C. Brewer ,&nbsp;Gideon Akintunde ,&nbsp;Faustina F. Blackie ,&nbsp;Lovelyn Charles ,&nbsp;Patricia Fast ,&nbsp;Paul-Henri Lambert ,&nbsp;Sylvanus Okogbenin ,&nbsp;Slobodan Paessler ,&nbsp;Daniel D. Pinschewer ,&nbsp;Karina A. Top ,&nbsp;Steven B. Black ,&nbsp;Cornelia L. Dekker","doi":"10.1016/j.vaccine.2024.126525","DOIUrl":"10.1016/j.vaccine.2024.126525","url":null,"abstract":"<div><div>Lassa virus (LASV) belongs to the Arenavirus family. LASV is endemic in several West Africa countries and causes viral hemorrhagic fevers. The Nigeria CDC has reported that an outbreak in 2024 in 28 states has resulted in 7767 suspected cases of Lassa fever, 971 confirmed cases and 166 confirmed deaths up to 11 August. Since infection with LASV can result in sensorineural hearing loss (SNHL) in up to 30% of patients, there are questions about whether triggering the immune response by immunization with LASV vaccines could potentially cause SNHL, although this has not been shown in clinical trials to date. To address this issue, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a three-hour webinar on 22 September 2023 to review what is known from both animal studies and human clinical trials and how hearing assessments in future clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for hearing assessment in expanded human trials of LASV vaccine candidates in children and adults.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126525"},"PeriodicalIF":4.5,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades","authors":"Felicity J. Coulter ,&nbsp;William B. Messer","doi":"10.1016/j.vaccine.2024.126423","DOIUrl":"10.1016/j.vaccine.2024.126423","url":null,"abstract":"<div><div>The yellow fever vaccine 17D is one of the most successful live-attenuated vaccines ever developed, controlling mosquito-borne yellow fever virus and yellow fever disease worldwide. Introduced in 1937, 17D never underwent rigorous phase III clinical trials to evaluate safety or efficacy, and while protection in the field was quickly established, no prospective evaluation of vaccine efficacy has ever been conducted. One important measure of vaccine efficacy is breakthrough infection resulting from vaccine failure. Yellow fever breakthrough infection was previously formally evaluated in a policy-changing report conducted by the Advisory Committee on Immunization Practices in 2015 but has not been reviewed since despite several recent outbreaks in South America and Africa. To address this knowledge gap, we conducted a literature search and reviewed 19 papers documenting breakthrough yellow fever infection between 1944 and 2023. There were up to 7793 suspected and up to 773 confirmed breakthrough cases reported in the literature, including thirteen cohort studies, four case reports, and two case series, which we summarize, evaluate the approaches used, and identify strengths and weakness. This review provides an important and much needed update on the topic of yellow fever breakthrough infection, drawing from recent outbreaks, highlighting limitations, and suggesting future approaches to further advance the field.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126423"},"PeriodicalIF":4.5,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142694089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How do national immunization technical advisory groups assess and use evidence: Findings from the SYSVAC survey","authors":"Antonia Pilic ,&nbsp;Louise Henaff ,&nbsp;Christoph Steffen ,&nbsp;Ole Wichmann ,&nbsp;Vanessa Piechotta ,&nbsp;Thomas Harder","doi":"10.1016/j.vaccine.2024.126538","DOIUrl":"10.1016/j.vaccine.2024.126538","url":null,"abstract":"<div><div>National immunization technical advisory groups (NITAGs) develop evidence-based vaccination recommendations. Systematic reviews (SRs) are important tools in that process, but conducting them is very resource-intensive. Given the considerable number of immunization-related SRs published and to minimize duplication of effort, a more practical approach for NITAGs is to use existing SRs. Among multiple initiatives and resources to strengthen NITAGs, the freely accessible SYSVAC registry supports NITAGs in identifying suitable SRs when developing vaccination recommendations. Additional SYSVAC courses provide step-by-step training on how to use SRs.</div><div>This cross-sectional survey was conducted online and involved 108 participants globally. The aim was to explore NITAGs user experience with evidence retrieval, to assess impact and use of the SYSVAC resources and training needs. Data were collected using a structured questionnaire.</div><div>Most of the respondents were &gt; 45 years old (75.9%) and represented 50 NITAGs from all six World Health Organization (WHO) regions. In total, 13/50 NITAGs (26.0%) had ease accessing full text publications. The preferred data sources to search for evidence were peer reviewed literature via PubMed and the WHO website (Strategic Advisory Group of Experts – SAGE – on Immunization). When developing vaccination recommendations, respondents stated using SRs mostly conducted by SAGE, other institutions or NITAGs (83.2%), recommendations of other countries (79.4%) and primary studies (73.8%). Respondents from 35 NITAGs stated to use the SYSVAC registry to search for evidence, leading to ≥69 recommendations being developed by NITAGs globally with its support. Aside existing SYSVAC courses on SR use, there was great interest in training on SR use in the development of vaccination recommendations.</div><div>Our survey gathered information on evidence use and training needs. Survey results serve as a starting point to improve support of NITAGs in developing recommendations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126538"},"PeriodicalIF":4.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Klebsiella pneumoniae bioconjugate vaccine functional durability in mice","authors":"Paeton L. Wantuch ,&nbsp;Cory J. Knoot ,&nbsp;Emily C. Marino ,&nbsp;Christian M. Harding ,&nbsp;David A. Rosen","doi":"10.1016/j.vaccine.2024.126536","DOIUrl":"10.1016/j.vaccine.2024.126536","url":null,"abstract":"<div><div><em>Klebsiella pneumoniae</em> is a leading cause of hospital-acquired infections as well as the leading cause of neonatal sepsis worldwide. Further, increasing antibiotic resistance in this pathogen makes <em>K. pneumoniae</em> troublesome to treat. Despite its clinical importance, there is not yet an approved <em>K. pneumoniae</em> vaccine available. Here we tested antibody durability and long-term functionality of two previously reported bioconjugate vaccines targeting the <em>K. pneumoniae</em> capsular type K2 and O-antigen type O1v1. We demonstrate that both antibodies are durable in mice for up to six months with significant IgG titers. However, only the K2 antibodies exhibit functionality out to six months as evidenced by serum bactericidal activity and survival in a murine bacteremia challenge model. These results are another promising step towards demonstrating the clinical capacity of bioconjugate vaccines and their induction of durable antibody responses.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"43 ","pages":"Article 126536"},"PeriodicalIF":4.5,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142690214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}